Zevra Therapeutics Inc
ZVRA8.810USD
-0.280-3.08%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
481.73MMarket Cap
LossP/E TTM
More Details of Zevra Therapeutics Inc Company
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Zevra Therapeutics Inc Info
Ticker SymbolZVRA
Company nameZevra Therapeutics Inc
IPO dateApr 16, 2015
CEOMr. Neil F. Mcfarlane
Number of employees59
Security typeOrdinary Share
Fiscal year-endApr 16
Address1180 Celebration Boulevard
CityCELEBRATION
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code34747
Phone13219393416
Websitehttps://zevra.com/
Ticker SymbolZVRA
IPO dateApr 16, 2015
CEOMr. Neil F. Mcfarlane
Company Executives of Zevra Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
222.02K
+15.93%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
45.00K
+12.50%
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
222.02K
+15.93%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
45.00K
+12.50%
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Revenue Breakdown
FY2025Q2
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
25.88M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Nov 8
Updated: Sat, Nov 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Woodline Partners LP
8.20%
Adage Capital Management, L.P.
7.40%
BlackRock Institutional Trust Company, N.A.
6.60%
The Vanguard Group, Inc.
5.48%
Fidelity Management & Research Company LLC
3.90%
Other
68.42%
Shareholders
Shareholders
Proportion
Woodline Partners LP
8.20%
Adage Capital Management, L.P.
7.40%
BlackRock Institutional Trust Company, N.A.
6.60%
The Vanguard Group, Inc.
5.48%
Fidelity Management & Research Company LLC
3.90%
Other
68.42%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.91%
Investment Advisor
21.76%
Investment Advisor/Hedge Fund
12.67%
Research Firm
2.14%
Private Equity
1.62%
Individual Investor
0.80%
Venture Capital
0.41%
Bank and Trust
0.10%
Pension Fund
0.04%
Other
33.56%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
256
37.37M
66.37%
-1.07M
2025Q2
239
33.85M
61.90%
-4.28M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Woodline Partners LP
4.62M
8.22%
+51.00
+0.00%
Jun 30, 2025
Adage Capital Management, L.P.
4.17M
7.42%
+550.00K
+15.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.72M
6.62%
-68.78K
-1.82%
Jun 30, 2025
The Vanguard Group, Inc.
2.95M
5.26%
+126.84K
+4.49%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.20M
3.92%
+10.59K
+0.48%
Jun 30, 2025
Rubric Capital Management LP
1.96M
3.49%
+740.58K
+60.82%
Jun 30, 2025
Nantahala Capital Management, LLC
1.47M
2.62%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.24M
2.21%
+9.28K
+0.75%
Jun 30, 2025
State Street Investment Management (US)
1.24M
2.21%
+65.11K
+5.53%
Jun 30, 2025
683 Capital Management LLC
1.13M
2%
-100.83K
-8.23%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Propel Opportunities ETF
2.11%
SPDR S&P Pharmaceuticals ETF
1.26%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.94%
Federated Hermes MDT Small Cap Core ETF
0.19%
iShares Micro-Cap ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.06%
Vanguard US Momentum Factor ETF
0.06%
iShares Biotechnology ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
View more
Simplify Propel Opportunities ETF
Proportion2.11%
SPDR S&P Pharmaceuticals ETF
Proportion1.26%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.94%
Federated Hermes MDT Small Cap Core ETF
Proportion0.19%
iShares Micro-Cap ETF
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Vanguard US Momentum Factor ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Russell 2000 Growth ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
